CVKD - Cadrenal Therapeutics, Inc. Stock Price and Quote

CVKD [NASD]

Index	-	P/E	-	EPS (ttm)	-	Insider Own	69.02%	Shs Outstand	11.63M	Perf Week	12.00%
Market Cap	16.55M	Forward P/E	-	EPS next Y	-	Insider Trans	0.37%	Shs Float	3.55M	Perf Month	-24.32%
Income	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float / Ratio	1.01% / 0.12	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Interest	0.04M	Perf Half Y	-
Book/sh	-	P/B	-	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	1.20 - 6.75	Perf YTD	-66.02%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-79.26%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	16.67%	ATR	0.20
Employees	1	Current Ratio	-	Sales Q/Q	-	Oper. Margin	-	RSI (14)	34.63	Volatility	10.66% 11.05%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.00	Prev Close	1.40
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	310.66K	Price	1.40
Recom	-	SMA20	-6.39%	SMA50	-31.56%	SMA200	-31.56%	Volume	0	Change	0.00%

Mar-30-23 09:00AM	Cadrenal Therapeutics Provides Fiscal Year 2022 Corporate Update PR Newswire +8.53%
Mar-09-23 09:00AM	Cadrenal Therapeutics Recognizes National Kidney Month with Goal to Advance Tecarfarin for Severely Underserved Patient Population PR Newswire -7.69%
Feb-08-23 09:00AM	Cadrenal Therapeutics to Ring the NASDAQ Stock Market Closing Bell on February 8, 2023 PR Newswire -9.26%
Feb-06-23 09:00AM	Cadrenal Therapeutics to Participate in the 2023 BIO CEO & Investor Conference PR Newswire -6.25%
Feb-01-23 09:00AM	Cadrenal Therapeutics Announces Formation of Scientific Advisory Board PR Newswire
02:11PM	Loading…
Jan-24-23 02:11PM	Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering PR Newswire -18.37%
Jan-23-23 11:39AM	What's Going On With Cadrenal Therapeutics Stock Today Benzinga
08:30AM	Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation PR Newswire
Jan-20-23 09:31AM	Cadrenal Therapeutics Announces Pricing of Initial Public Offering (IPO) PR Newswire

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MURPHY JOHN RAYMOND	Director	Mar 21	Buy	1.39	10,000	13,900	594,792	Mar 22 04:01 PM
MURPHY JOHN RAYMOND	Director	Mar 16	Buy	1.67	20,000	33,398	574,792	Mar 16 05:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience